Chase C. Leavitt serves as Executive at Lineage Cell Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Chase C. Leavitt has executed 11 insider transactions totaling $43.8K, demonstrating a bullish approach to their equity position. Their most recent transaction on Jan 3, 2024 involved selling 11,838 shares valued at $5.9K.
Chase C. Leavitt currently holds 84,758 shares of Lineage Cell Therapeutics, Inc. (LCTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Chase C. Leavitt has been a net buyer of LCTX stock. They have purchased $43.8K and sold $0 worth of shares.
Chase C. Leavitt's most recent insider trade was on Jan 3, 2024, when they sold 11,838 shares at $0.50 per share.
Get notified when new Form 4 filings are submitted
| $0.36 |
| Discretionary |
| Apr 13, 2023 | ONCT | $2.9K | Purchase | 10,000 | $0.29 | Discretionary |
| Apr 12, 2023 | ONCT | $4.3K | Purchase | 15,000 | $0.29 | Discretionary |
| Jan 3, 2023 | ONCT | $6.2K | Payment | 6,091 | $1.02 | Discretionary |
| Jul 28, 2022 | ONCT | $0 | Award | 43,125 | $N/A | Discretionary |
| Jan 28, 2022 | ONCT | $8.2K | Purchase | 5,000 | $1.63 | Discretionary |
| Jan 27, 2022 | ONCT | $15.1K | Purchase | 8,500 | $1.78 | Discretionary |
| Jan 3, 2022 | ONCT | $0 | Award | 29,867 | $N/A | Discretionary |
| Jun 11, 2021 | ONCT | $8.2K | Purchase | 1,500 | $5.45 | Discretionary |
| Aug 13, 2019 | LCTX | $5.1K | Purchase | 5,000 | $1.02 | Discretionary |